Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis

Claudia Marchetti; Francesca De Felice; Angela Musella; Innocenza Palaia; Marco Monti; Daniela Musio; Ludovico Muzii; Vincenzo Tombolini; Pierluigi Benedetti Panici

doi:10.18632/oncotarget.11094

Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis

Claudia Marchetti, Francesca De Felice, Angela Musella, Innocenza Palaia, Marco Monti, Daniela Musio, Ludovico Muzii, Vincenzo Tombolini, Pierluigi Benedetti Panici

University of Rome La Sapienza

Research output: Contribution to journal › Article

Abstract

Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a metaanalysis to compare the two regimens. Method: Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity. Results: Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77- 1.16, p=0.06), as well as in term of severe acute toxicity. Conclusion: Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.

Original language	English
Pages (from-to)	58709-58715
Number of pages	7
Journal	Oncotarget
Volume	7
DOIs	https://doi.org/10.18632/oncotarget.11094
Publication status	Published - 2016

Keywords

Carboplatin
Dose-dense
Ovarian cancer
Paclitaxel
Weekly

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.18632/oncotarget.11094

Cite this

@article{952424bcd2944111ab2f58c3198b558f,

title = "Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis",

abstract = "Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a metaanalysis to compare the two regimens. Method: Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity. Results: Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77- 1.16, p=0.06), as well as in term of severe acute toxicity. Conclusion: Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.",

keywords = "Carboplatin, Dose-dense, Ovarian cancer, Paclitaxel, Weekly, Carboplatin, Dose-dense, Ovarian cancer, Paclitaxel, Weekly",

author = "Claudia Marchetti and {De Felice}, Francesca and Angela Musella and Innocenza Palaia and Marco Monti and Daniela Musio and Ludovico Muzii and Vincenzo Tombolini and Panici, {Pierluigi Benedetti}",

year = "2016",

doi = "10.18632/oncotarget.11094",

language = "English",

volume = "7",

pages = "58709--58715",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

}

TY - JOUR

T1 - Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis

AU - Marchetti, Claudia

AU - De Felice, Francesca

AU - Musella, Angela

AU - Palaia, Innocenza

AU - Monti, Marco

AU - Musio, Daniela

AU - Muzii, Ludovico

AU - Tombolini, Vincenzo

AU - Panici, Pierluigi Benedetti

PY - 2016

Y1 - 2016

N2 - Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a metaanalysis to compare the two regimens. Method: Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity. Results: Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77- 1.16, p=0.06), as well as in term of severe acute toxicity. Conclusion: Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.

AB - Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a metaanalysis to compare the two regimens. Method: Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity. Results: Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77- 1.16, p=0.06), as well as in term of severe acute toxicity. Conclusion: Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.

KW - Carboplatin

KW - Dose-dense

KW - Ovarian cancer

KW - Paclitaxel

KW - Weekly

KW - Carboplatin

KW - Dose-dense

KW - Ovarian cancer

KW - Paclitaxel

KW - Weekly

UR - http://hdl.handle.net/10807/205127

U2 - 10.18632/oncotarget.11094

DO - 10.18632/oncotarget.11094

M3 - Article

SN - 1949-2553

VL - 7

SP - 58709

EP - 58715

JO - Oncotarget

JF - Oncotarget

ER -

Weekly versus three weeks chemotherapy for advanced ovarian cancer: A meta-analysis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this